控制肿瘤转移是肿瘤治疗成败的重要因素之一.就转移能力而言,原发性肿瘤也呈细胞异质性.因此,控制转移颇为困难亦较复杂。最近Fidler 和他的同事证明,静脉注射含巨噬细胞激活剂,诸如LYNK(粗提淋巴激活素)或胞壁酰基二肽的脂质体,能有效地抑制有同基因型的恶性黑色素瘤小鼠的肺转移.作者曾在患纤维肉瘤T_(241)的小鼠中使用含LYNK 的脂质体进行试验治疗,同样观察到其对小鼠肺转移的抑制。也指出,若用脂质体包裹高纯度的人体CRP 也产生LYNK 抑制转移的作用。上述实 Controlling tumor metastasis is one of the important factors in the success or failure of tumor treatment. In terms of metastatic ability, primary tumors also show cellular heterogeneity. Therefore, control of metastasis is difficult and complicated. Recently, Fidler and his colleagues have demonstrated that intravenous injection of liposomes containing macrophage activators, such as LYNK (lipolysin) or muramyl dipeptides, can effectively inhibit melanomas with isotypes Lung metastasis in mice. The authors used LYNK-containing liposomes for experimental treatment in mice with fibrosarcoma T_(241) and observed inhibition of lung metastasis in mice. It is also pointed out that if high purity human CRP is encapsulated with liposomes, it also produces LYNK to inhibit metastasis. The above